Cellectar BioSciences sells 2,116,887 unregistered shares in private placement

Cellectar Biosciences

Cellectar Biosciences

CLRB

0.00
  • Cellectar BioSciences entered a concurrent private placement on May 4, 2026, alongside a registered direct offering.
  • Private placement covers 2,116,887 unregistered common shares, pre-funded warrants for 9,471,086 shares, and 13,206,026 milestone-based warrants in each of Tranche A, Tranche B, Tranche C.
  • Milestone warrants require stockholder approval to become exercisable, carry a $2.65 exercise price, and run for 1 year, 2 years, and 5 years, respectively.
  • Company can call Tranche A upon initiation of randomized confirmatory pivotal trial for iopofosine I 131, Tranche B upon FDA acceptance for review of NDA, Tranche C upon FDA approval of NDA.
  • Call feature requires common stock to trade above 130% of exercise price for 20 straight sessions, with average daily volume of at least $500,000.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-057460), on May 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.